Navigation Links
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
Date:12/9/2009

endogenous expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct angiogenic, neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About the Study, SB-509-801

A total of 45 subjects with ALS were enrolled in this trial and randomized into one of two treatment cohorts. The first cohort (38 subjects) received 60 mg of SB-509 in a divided dose into muscles in the neck, arms and legs. The second cohort (7 subjects) received 60 mg of SB-509 in a divided dose into the muscles in the lower limb in both legs. Each subject receives a total of two treatments of 60 mg of SB-509 intramuscularly three months apart on Day 0 and Day 90 and is followed for six months after administration of the final dose.

Details of Presentation of Preliminary Data from SB-509-801 Study

Wednesday, December 9, 2009

  • "Plasmid Gene Transfer of Zinc Finger Protein VEGF-A Transcription Activator (SB-509) for Treatment of Amyotrophic Lateral Sclerosis - A Phase 2 Clinical Trial of SB-509 in ALS." *E. Benaim, S. Hamilton, D. Moore and D. Ando, Sangamo BioSciences, Inc., Richmond, California.

Preliminary data were presented from Sangamo's open-label, repeat dosing, Phase 2 clinical study (SB-509-801) in which subjects with ALS were treated at 0 and 90 days with SB-509 in one of two injection patterns. All subjects will be followed for up to 270 days post initial treatment. A total of 45 subjects are enrolled in the study; data are presented here from 22 subjects up to a time point of 120 days post treatment. There were no drug related severe adverse events and the drug was well-tolerated.

In manual mu
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo Announces Closing of Common Stock Offering
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
5. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... , May 23, 2013  Omeros Corporation ... its Investigational New Drug Application (IND) to evaluate ... the U.S. Food and Drug Administration (FDA). OMS824 ... in areas of the brain linked to a ... Huntington,s disease and schizophrenia. OMS824 has shown promising ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
... N.D., Dec. 16, 2011  Crystal3 Labs, Inc., a cGMP contract ... today that it has been acquired by an individual ... of the transaction were not disclosed. The company also ... Founded in 2007, Global Pharma Analytics provides ...
... ( Medical Device and Diagnostic Industry , UBM ... latest news , information, and in-depth analysis, announced a series of ... of medical device design.  "We,re taking a close ... industry," stated Brian Buntz, Editor for MD+DI. "To some, the focus ...
Cached Medicine Technology:Crystal3 Labs Acquired by Individual Investor, Vithalbhai Dhaduk, M.D. 2MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation 2MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation 3
(Date:5/23/2013)... 2013 The sodium theory ... and B. Katz in the early 1950s, after their ... of sodium and potassium ions in nerve functions ... acquisition techniques have known amazing developments. In The Sodium ... give an account of the latest developments in the ...
(Date:5/23/2013)... 2013 Orange County film studio and visual ... light leaks for Apple's Final Cut Pro X ... you no longer have to worry about matching up the ... shot," Said Christina Austin, CEO of Pixel Film Studios, "You ... natural look." , ProLeak from Pixel Film Studios allows users ...
(Date:5/23/2013)... Dr. Damon Huffman of Huffman Family Dentistry is ... a revolutionary new treatment method with the Laser Assisted New ... suffer from periodontal disease, and many of them do not ... is hoping that LANAP will encourage many of those people ... , Periodontal disease can cause gums to recede and even ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... Lake City, UT (PRWEB) May 23, 2013 ... 3.0 , a comprehensive radiology learning environment for ... with prebuilt lessons and assessments, transforms the learning ... comprehensive radiology curriculum. , “Until RADPrimer ... is second to none,” comments Dr. B.J. Manaster, ...
Breaking Medicine News(10 mins):Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2
... African swine fever, a devastating pig disease that could ... Organisation said Friday. ,"This is a dramatic ... the Rome-based FAO, noting that the highly contagious viral ... since 1990." ,Armenia, Azerbaidjan and Russia "should ...
... survivors can halve the risk of dying from the disease ... of their weight, suggests a longitudinal study from the ... (UCSD). ,Published in the Journal of Clinical Oncology, ... of a combination of both healthy diet and physical activity ...
... aging in fruit flies with a new technique that shows ... triumph for pests, scientists have found out how to make ... may still have something for humans. As reported online in ... slow down aging holds implications for humans prolonged existence and ...
... diagnosed cancer in men. More than 218,000 men will be ... 27,000 will die . June is Prostate Cancer Awareness Month, ... about the ways men can keep their prostates healthy and ... caused by benign prostatic enlargement affect the vast majority of ...
... department of Health today confirmed the death of a Madison County ... case in 2007 and it seems to be much earlier ... due to the virus. ,Four Mississippians have contracted West ... according to the Health Department and the Centers for Disease Control ...
... gave birth to twins at a hospital in London, where she ... ,The 47-year-old and her husband of ten years, Paul Berges, ... only next month. ,Predicting the early arrival of twins, ... and that she and Berges are really thrilled about it. ...
Cached Medicine News:Health News:Healthy Diet, Exercise can Halve the Risk of Mortality in Breast Cancer Survivors 2Health News:Super Fruit Fly may Harbor Hope for Human Longevity 2Health News:Tips to Maintain a Healthy Prostate 2Health News:First Case of West Nile Virus Death in Madison County 2
... nonsurgical, physician-administered treatment that can temporarily smooth ... brows in people from 18 to 65 ... treatment of its type approved by the ... Cosmetic is a purified protein produced by ...
... is a non-animal stabilized hyaluronic acid-based ... filler to enter the U.S. market. ... moderate to severe facial wrinkles and ... is injected just under the skins ...
... SCULPTRA™ is an injectable ... poly-L-lactic acid, a biocompatible, biodegradable, ... family. SCULPTRA is reconstituted prior ... of Sterile Water for Injection, ...
... is clinically proven to reduce the appearance ... cream-gel formula combines Retinol, the purest form ... Caffeine. It works deep within skin's surface ... bumpy appearance. Fast absorbing, it has a ...
Medicine Products: